Preliminary report: cyclosporin in treatment of severe active ulcerative colitis - PubMed (original) (raw)
Preliminary report: cyclosporin in treatment of severe active ulcerative colitis
S Lichtiger et al. Lancet. 1990.
Abstract
Intravenous cyclosporin (4 mg/kg daily) was given to fifteen patients with severe active ulcerative colitis, fourteen of whom had failed to respond to at least 10 days' treatment with intravenous steroids. In the acute phase of the open trial, eleven patients (73%) improved and avoided colectomy; the mean response time was 5.8 days. Patients who responded were maintained on oral cyclosporin (6-8 mg/kg daily) for a 6-month chronic phase. Six of the eleven patients have been weaned from steroids and remain in clinical and endoscopic remission 5-18 months after discontinuation of cyclosporin; three are well at 5 months and their steroid dose is being tapered; one patient relapsed after 5 months on oral cyclosporin and underwent colectomy; and one patient failed to show continued improvement with oral cyclosporin but is in clinical remission after changing to mercaptopurine treatment. Slight self-limiting adverse side-effects of cyclosporin were seen, but none necessitated withdrawal from the study. Cyclosporin seems to be an effective treatment for patients with severe active ulcerative colitis who have not responded to steroids.
Comment in
- Cyclosporin treatment for severe active ulcerative colitis.
Bianchi Porro G, Petrillo M, Ardizzone S. Bianchi Porro G, et al. Lancet. 1990 Aug 18;336(8712):439. doi: 10.1016/0140-6736(90)91984-i. Lancet. 1990. PMID: 1974964 No abstract available.
Similar articles
- Cyclosporin for the treatment of severe ulcerative colitis.
Wenzl H, Petritsch W, Reicht G, Eherer A, Krejs GJ. Wenzl H, et al. Z Gastroenterol. 1994 Mar;32(3):137-40. Z Gastroenterol. 1994. PMID: 8197807 - Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis.
Stack WA, Long RG, Hawkey CJ. Stack WA, et al. Aliment Pharmacol Ther. 1998 Oct;12(10):973-8. doi: 10.1046/j.1365-2036.1998.00396.x. Aliment Pharmacol Ther. 1998. PMID: 9798801 Clinical Trial. - Intravenous cyclosporin in ulcerative colitis: a five-year experience.
Cohen RD, Stein R, Hanauer SB. Cohen RD, et al. Am J Gastroenterol. 1999 Jun;94(6):1587-92. doi: 10.1111/j.1572-0241.1999.01149.x. Am J Gastroenterol. 1999. PMID: 10364029 - [Management of ulcerative colitis].
Rammert Ch, Kullak-Ublick GA. Rammert Ch, et al. Ther Umsch. 2003 Mar;60(3):145-50. doi: 10.1024/0040-5930.60.3.145. Ther Umsch. 2003. PMID: 12693317 Review. German. - Ulcerative colitis: conservative management and long-term effects.
Kühbacher T, Schreiber S, Fölsch UR. Kühbacher T, et al. Langenbecks Arch Surg. 2004 Oct;389(5):350-3. doi: 10.1007/s00423-004-0477-8. Epub 2004 May 5. Langenbecks Arch Surg. 2004. PMID: 15133672 Review.
Cited by
- Predictors of the efficacy of vedolizumab in patients with ulcerative colitis.
Kajikawa G, Sawada T, Nakamura M, Yamamura T, Maeda K, Ishikawa E, Uetsuki K, Hirose T, Iida T, Mizutani Y, Yamao K, Ishikawa T, Furukawa K, Kawashima H. Kajikawa G, et al. Nagoya J Med Sci. 2024 Aug;86(3):407-421. doi: 10.18999/nagjms.86.3.407. Nagoya J Med Sci. 2024. PMID: 39355361 Free PMC article. - Early Sonographic Improvement Predicts Clinical Remission and Mucosal Healing With Molecular-Targeted Drugs in Ulcerative Colitis.
Kimura Y, Miyoshi J, Morikubo H, Komatsu H, Moue C, Yonezawa H, Matsuura M, Hisamatsu T. Kimura Y, et al. Gastro Hep Adv. 2024 Apr 23;3(6):703-710. doi: 10.1016/j.gastha.2024.04.007. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39280912 Free PMC article. - Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research.
Vuyyuru SK, Nardone OM, Jairath V. Vuyyuru SK, et al. J Clin Med. 2024 Aug 1;13(15):4509. doi: 10.3390/jcm13154509. J Clin Med. 2024. PMID: 39124775 Free PMC article. Review. - Successful Fistula Closure After Treatment with Colostomy and Infliximab in a Patient with Ulcerative Colitis Complicated by Rectovaginal Fistula.
Katsube S, Matsumoto S, Misawa M, Kakizawa N, Hashimoto R, Mizutani T, Matsumoto K, Yoshikawa S, Mashima H. Katsube S, et al. Biologics. 2024 May 6;18:107-113. doi: 10.2147/BTT.S457300. eCollection 2024. Biologics. 2024. PMID: 38736705 Free PMC article. - Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease.
Gara SK, Guntipalli P, Marzban S, Taqi M, Aryal V, Khan QUA, Shah SA, Akbariromani H, Salinger D, Diaz-Miret M. Gara SK, et al. Cureus. 2023 Oct 11;15(10):e46833. doi: 10.7759/cureus.46833. eCollection 2023 Oct. Cureus. 2023. PMID: 37954750 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical